Literature DB >> 19265444

Thermodynamics of lipophilic drug binding to intestinal fatty acid binding protein and permeation across membranes.

Tony Velkov1.   

Abstract

Intestinal fatty acid binding protein (I-FABP) is present at high levels in the absorptive cells of the intestine (enterocytes), where it plays a role in the intracellular solubilization of fatty acids (FA). However, I-FABP has also been shown to bind to a range of non-FA ligands, including some lipophilic drug molecules. Thus, in addition to its central role in FA trafficking, I-FABP potentially serves as an important intracellular carrier of lipophilic drugs. In this study we provide a detailed thermodynamic analysis of the binding and stability properties of I-FABP in complex with a series of fibrate and fenamate drugs to provide an insight into the forces driving drug binding to I-FABP. Drug binding and selectivity for I-FABP are driven by the interplay of protein-ligand interactions and solvent processes. The Gibbs free energies (deltaGo) determined from dissociation constants at 25 degrees C ranged from -6.2 to -10 kcal/mol. The reaction energetics indicate that drug binding to I-FABP is an enthalpy-entropy driven process. The relationship between I-FABP stability and drug binding affinity was examined by pulse proteolysis. There is a strong coupling between drug binding and I-FABP stability. The effect of an I-FABP protein sink on the kinetics and thermodynamics of tolfenamic acid permeation across an artificial phospholipid membrane were investigated. I-FABP significantly decreased the energy barrier for desorption of tolfenamic acid from the membrane into the acceptor compartment. Taken together, these data suggest that the formation of stable drug-I-FABP complexes is thermodynamically viable under conditions simulating the reactant concentrations likely observed in vivo and maybe a significant biochemical process that serves as a driving force for passive intestinal absorption of lipophilic drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19265444     DOI: 10.1021/mp800227w

Source DB:  PubMed          Journal:  Mol Pharm        ISSN: 1543-8384            Impact factor:   4.939


  7 in total

1.  Fatty acid binding proteins: potential chaperones of cytosolic drug transport in the enterocyte?

Authors:  Natalie L Trevaskis; Gary Nguyen; Martin J Scanlon; Christopher J H Porter
Journal:  Pharm Res       Date:  2011-04-27       Impact factor: 4.200

2.  Fatty Acid Binding Proteins Expressed at the Human Blood-Brain Barrier Bind Drugs in an Isoform-Specific Manner.

Authors:  Gordon S Lee; Katharina Kappler; Christopher J H Porter; Martin J Scanlon; Joseph A Nicolazzo
Journal:  Pharm Res       Date:  2015-08-07       Impact factor: 4.200

3.  Direct interaction between EgFABP1, a fatty acid binding protein from Echinococcus granulosus, and phospholipid membranes.

Authors:  Jorge L Porfido; Gabriela Alvite; Valeria Silva; Malcolm W Kennedy; Adriana Esteves; Betina Corsico
Journal:  PLoS Negl Trop Dis       Date:  2012-11-15

4.  Combinations of protein-chemical complex structures reveal new targets for established drugs.

Authors:  Olga V Kalinina; Oliver Wichmann; Gordana Apic; Robert B Russell
Journal:  PLoS Comput Biol       Date:  2011-05-05       Impact factor: 4.475

5.  The thermodynamics of Pr55Gag-RNA interaction regulate the assembly of HIV.

Authors:  Hanumant S Tanwar; Keith K Khoo; Megan Garvey; Lynne Waddington; Andrew Leis; Marcel Hijnen; Tony Velkov; Geoff J Dumsday; William J McKinstry; Johnson Mak
Journal:  PLoS Pathog       Date:  2017-02-21       Impact factor: 6.823

6.  Activity Screening of Fatty Acid Mimetic Drugs Identified Nuclear Receptor Agonists.

Authors:  Moritz Helmstädter; Simone Schierle; Laura Isigkeit; Ewgenij Proschak; Julian Aurelio Marschner; Daniel Merk
Journal:  Int J Mol Sci       Date:  2022-09-03       Impact factor: 6.208

7.  Interactions between Human Liver Fatty Acid Binding Protein and Peroxisome Proliferator Activated Receptor Selective Drugs.

Authors:  Tony Velkov
Journal:  PPAR Res       Date:  2013-02-18       Impact factor: 4.964

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.